OraSure is experiencing strong international demand for its HIV self-test that's offsetting declining sales growth in the domestic HIV segment.
The firm, which raised $7.1 million from its IPO last week, is looking to move into geographies where a need for infectious disease tests are already well established, its CEO said.
Promega would first seek clearance for an assay that detects dMMR in colorectal cancer patients, and could seek a far broader clearance in the long term.
A diagnostic test could be available within about a year that researchers and clinicians could use to diagnose patients and develop therapies.
Researchers from the University of Illinois said their test may one day enable patients to identify sepsis at home and transmit test results immediately to a physician.
The researchers are developing a clinical assay that would use multiple biomarkers to analyze low-abundance peptides indicative of preterm risk.
The researchers found that Cepheid's Xpert HCV viral load assay used at the point of care performed at levels comparable to a laboratory test.
Researchers are working with the Australian Ministry of Health to commercialize a diagnostic test that employs the biomarker and could be available within two to five years.
An Alberta-based research group plans to launch a blood test that could improve the specificity of prostate cancer diagnosis and reduce the number of biopsies.
The deal is anticipated to increase diagnostics' share of PerkinElmer's business to about 38 percent of total revenues from the current 30 percent.